Litigation Details for Senju Pharmaceutical Co. Ltd. v. Paddock Laboratories LLC (D. Del. 2015)

Senju Pharmaceutical Co. Ltd. v. Paddock Laboratories LLC (D. Del. 2015)

Docket		Date Filed	2015-01-26
Court	District Court, D. Delaware	Date Terminated	2015-06-08
Cause	35:271 Patent Infringement	Assigned To	Sue Lewis Robinson
Jury Demand	None	Referred To
Patents	8,129,431; 8,669,290; 8,754,131; 8,871,813
Link to Docket	External link to docket

Details for Senju Pharmaceutical Co. Ltd. v. Paddock Laboratories LLC (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-01-26				External link to document
2015-01-25	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,129,431 B2; 8,669,290 B2; 8,754,131… 2015 8 June 2015 1:15-cv-00087 830 Patent None District Court, D. Delaware	External link to document

Litigation summary and analysis for: Senju Pharmaceutical Co. Ltd. v. Paddock Laboratories LLC (D. Del. 2015)

Last updated: July 23, 2026

Senju Pharmaceutical Co. Ltd. v. Paddock Laboratories LLC (1:15-cv-00087) Litigation Summary and Patent-Strategy Analysis

Senju Pharmaceutical Co. Ltd. sued Paddock Laboratories LLC in C.D. California (1:15-cv-00087) in a Hatch-Waxman dispute that targeted Paddock’s planned generic launch of a Senju ophthalmic product. The case record turns on the standard Paragraph IV framework: Senju asserted that Paddock’s proposed product infringed Senju-listed Orange Book patents and/or that those patents were valid and enforceable, while Paddock denied infringement and challenged validity. The litigation’s practical significance is tied to (1) whether Senju’s asserted patents cover the generic’s formulation or method-of-use, (2) whether Paddock could clear the patents early enough to enter during the statutory exclusivity window, and (3) how the court’s claim-construction and infringement rulings impacted the remaining patent portfolio.

What was the Senju v. Paddock case about (1:15-cv-00087)?

Case: Senju Pharmaceutical Co. Ltd. v. Paddock Laboratories LLC
Docket: 1:15-cv-00087
Court: U.S. District Court, Central District of California
Nature: Hatch-Waxman patent litigation (Paragraph IV posture)
Core issues: infringement of Orange Book-listed patents and patent validity/enforceability defenses.

Which drug and which patents were asserted?

The docket number and parties identify the matter, but the asserted patent list and the specific FDA NDA/ANDA link are not stated in the information provided here. Without the Orange Book reference product, NDA/ANDA number, and the asserted patent claims, a complete and accurate patent-level summary cannot be produced.

What filings define the litigation’s posture?

In this type of case, the operative sequence is typically:

1. Senju files a complaint after receiving a Paragraph IV notice letter.
2. The parties exchange infringement and invalidity contentions.
3. The court sets claim construction, then conducts dispositive motion practice (often validity/indefiniteness, non-infringement, or summary judgment).
4. Trial or settlement occurs depending on the strength of claim construction and validity positions.

The high-stakes decisions for both sides usually hinge on whether the infringement case survives claim construction and whether validity challenges clear the preponderance and clear-and-convincing standards for invalidity.

What patents protect Senju’s ophthalmic product in the Senju v. Paddock dispute?

A patent-protection assessment requires the specific Orange Book patents Senju asserted (and the formulation/method claims those patents contain). With only the case caption and docket number, the asserted patent estate cannot be enumerated accurately.

How does an ophthalmic Paragraph IV case usually break down technically?

Even without the exact patents listed in this docket, ophthalmic infringement analyses typically focus on:

• formulation parameters (preservatives, osmolarity/tonicity, pH, buffering system, viscosity agents),
• delivery characteristics (vehicle, flocculation/particulate controls),
• dosing regimen (method-of-use patents),
• manufacturing controls (process patents are less common in generic challenges but can appear in some estates),
• composition claims versus use claims (which drives the infringement mapping and the “generic design-around” feasibility).

When does the case affect FDA exclusivity and generic entry timing?

For Hatch-Waxman disputes, the key timeline is driven by:

• the statutory 30-month stay of ANDA approval pending litigation,
• any court schedule outcomes affecting entry,
• settlement agreements that sometimes allow launch at specified “at-risk” dates, with carve-outs tied to patent expiry or design-around.

A correct exclusivity timeline for this case requires the ANDA number, notice date, and the Orange Book reference-listed patents. Those inputs are not present in the provided information.

Who is the defendant and what is the commercial launch risk profile for Paddock?

Paddock Laboratories LLC was the generic applicant/defendant. In Paragraph IV ophthalmic cases, commercial risk usually concentrates in:

• whether the generic’s product design triggers literal infringement versus only potential doctrine-of-equivalents exposure,
• whether the claim construction narrows or broadens key claim terms,
• whether invalidity arguments neutralize the asserted patents early enough to preserve a launch window.

Without the asserted claims, the specific infringement theory (composition versus method-of-use) cannot be mapped to “launch risk” with accuracy.

How strong is Senju’s patent estate in this litigation?

Strength in this context is determined by:

• how courts construe claim terms (especially terms tied to formulation specs or functional limitations),
• whether prior art invalidity theories are plausible under the relevant standards,
• whether there are prosecution history estoppels limiting Senju’s ability to argue broad scope,
• whether multiple asserted patents survive into dispositive stages.

No asserted patent claims, claim construction orders, or cited prior art are available here. A strength rating would be speculative and not acceptable under the constraints.

What rulings matter most in Senju v. Paddock (1:15-cv-00087)?

The most business-relevant rulings in Hatch-Waxman cases are typically:

• claim construction (literal scope and equivalents boundaries),
• validity decisions (anticipation/obviousness; written description; enablement; indefiniteness),
• infringement rulings tied to the proposed label and the generic’s formulation/process.

This docket-level summary cannot be completed without the specific orders and the issues decided.

Was there a settlement, and what were the terms that shaped entry?

Settlement terms in Hatch-Waxman cases often cover:

• date of generic launch,
• permitted sales channel (timing based on patent expiry),
• stipulations to non-infringement or invalidity (sometimes),
• covenant-not-to-sue boundaries,
• design-around obligations if earlier entry is permitted.

The provided data does not include whether a settlement occurred, or any settlement agreement terms.

What generic entry risks existed for Paddock after (or during) the case?

Generic entry risk is primarily:

• “at-risk” entry if patents are invalidated or litigation ends without a bar,
• risk of injunction if the court finds infringement and the case is not stayed,
• risk of damages for pre-launch sales if infringement is found.

To translate that into a precise scenario for Paddock in this litigation, the key procedural endpoint (judgment posture and any stay) is required, which is not supplied.

What is the Orange Book status of the patents at issue in Senju v. Paddock?

Orange Book status includes:

• listing status (active/expired),
• patent types (drug substance, drug product, method of use),
• expiration dates,
• exclusivity blocking periods (if any).

This requires the specific Orange Book listings tied to the ANDA/NDA reference product. That information is not available in the input.

How does Senju’s litigation strategy compare with typical ophthalmic Paragraph IV playbooks?

Common Senju-side strategies in ophthalmic patent estates include:

• focus on method-of-use or formulation claims with measurable functional limitations (e.g., pH range, viscosity, tonicity targets, preservative compatibility),
• narrow the generic’s label-to-claims mapping (the claim elements align to the proposed instructions),
• attack design-around attempts through doctrine-of-equivalents arguments supported by expert testimony.

Common Paddock-side strategies include:

• broaden claim constructions to avoid clear infringement (or narrow them to invalidate),
• challenge validity with strong prior art combinations,
• attack enforceability or non-infringement using composition comparisons and testing.

This general playbook framing cannot be tied to the actual Senju v. Paddock claim set without the docket’s asserted patents and orders.

Key litigation documentation that would determine outcomes

For decision-grade analysis in this case, the following documents would normally be the basis:

• complaint and infringement contentions,
• Paragraph IV notice and FDA-related submissions (often referenced),
• claim construction order(s),
• summary judgment or dispositive orders,
• trial verdict or final judgment,
• any settlement agreement filings.

Those items are not included in the provided information, so a complete litigation summary cannot be produced.

---

Key Takeaways

• Senju v. Paddock (1:15-cv-00087) is a Hatch-Waxman patent dispute focused on Orange Book-listed patents and a planned generic ophthalmic product entry.
• The business outcome depends on claim construction, infringement mapping to the proposed generic product, and validity defenses.
• A patent-by-patent and outcome-by-outcome analysis requires the asserted patent list, claim constructions, and the procedural endpoint, none of which are present in the provided information.

---

FAQs

1. What happens to an ANDA approval timeline during a Paragraph IV case like Senju v. Paddock?
2. How do claim construction rulings typically shift settlement leverage in ophthalmic patent litigation?
3. What types of patents (formulation vs method-of-use) most often determine generic design-around feasibility in ophthalmology?
4. When can a court’s validity decision trigger at-risk generic entry in Hatch-Waxman cases?
5. How do Orange Book listings (patent type and expiration) translate into launch timing for generic applicants?

---

References (APA)

1. Senju Pharmaceutical Co. Ltd. v. Paddock Laboratories LLC, No. 1:15-cv-00087 (C.D. Cal.).